SCHEMBL752472

SCHEMBL752472

CCNC(=O)Nc1cccc(Nc2nc3ccccn3c2-c2cc(N)nc(C)n2)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 11/20 0.54
MTOR P42345 11/20 0.54
FGFR3 P22607 3/20 0.45
KDR P35968 3/20 0.45
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KIT P10721 1/20 0.38
DDR1 Q08345 1/20 0.38
DDR2 Q16832 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2775861 0.93 PIK3CA (0.56) PIK3CAMTORFGFR3KDRCCNE1
SCHEMBL11027619 0.91 PIK3CA (0.60) PIK3CAMTORFGFR3KDRCCNE1
SCHEMBL751742 0.91 PIK3CA (0.52) PIK3CAMTORFGFR3KDRCCNE1
SCHEMBL751149 0.90 PIK3CA (0.57) PIK3CAMTORFGFR3KDRCCNE1
SCHEMBL756108 0.88 PIK3CA (0.59) PIK3CAMTORCCNE1CDK2PIK3CD
SCHEMBL749918 0.88 PIK3CA (0.54) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL750596 0.87 PIK3CA (0.56) PIK3CAMTORFGFR3KDRCCNE1
SCHEMBL2773726 0.86 PIK3CA (0.51) PIK3CAMTORFGFR3KDRCCNE1
SCHEMBL756457 0.86 PIK3CA (0.56) PIK3CAMTORKDM4EGAARAB9A
SCHEMBL2790005 0.85 PIK3CA (0.62) PIK3CAMTORFGFR3KDRCCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885FGFR3 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.